Search results
Moderna says next-generation COVID vaccine efficacy non-inferior to current shot
Reuters via Yahoo News· 6 days agoThe experimental vaccine, which met the main trial goal, was being tested in more than 11,000 people...
Gateway - Quartz
Quartz· 8 hours agoNovo Nordisk responded this week to the Federal Trade Commission’s (FTC) suggestion that it filed ‘junk’ patents to prevent competition and raise prices. Moderna stock surged ...
Gateway - Quartz
Quartz· 8 hours agoA new study found that Novo Nordisk’s nearly $1,000 per month diabetes medication Ozempic can be produced for less than $5 a month. Novo Nordisk and Johnson & Johnson both announced billion-dollar ...
Moderna says next-gen COVID shot effective in study
BioPharma Dive via Yahoo Finance· 6 days agoTrial data suggest the shot — an important component of an upcoming combination inoculation — has proven at least as effective, and in some cases...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation...
Morningstar· 6 days agoCAMBRIDGE, MA / ACCESSWIRE / June 13, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1283, an investigational next-generation COVID-19 vaccine ...
Oppenheimer Increases Moderna (NASDAQ:MRNA) Price Target to $179.00
ETF DAILY NEWS· 5 days agoModerna (NASDAQ:MRNA – Get Free Report) had its target price hoisted by analysts at Oppenheimer from $163.00 to $179.00 in a research report issued to clients and investors ...
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Zacks· 4 days agoData from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Moderna, Inc. (NASDAQ:MRNA) Director Sells $30,088,098.88 in Stock
ETF DAILY NEWS· 7 days agoModerna, Inc. (NASDAQ:MRNA – Get Free Report) Director Noubar Afeyan sold 202,832 shares of the stock in a transaction that occurred on Tuesday, June 11th. The shares were ...
Moderna’s next-gen COVID vaccine shows non-inferiority to its current shot
WSAU Wausau· 6 days ago(Reuters) -Moderna said on Thursday its next-generation COVID-19 vaccine candidate met its main goal...
Moderna’s Covid-19 vaccine meets primary efficacy endpoint in Phase III trial
Clinical Trials Arena via Yahoo Finance· 5 days agoModerna has announced that its Phase III clinical trial of the investigational next-generation...
